Hormonal
Intermittent Fasting (IF) in normal-weight subjects may cause adverse metabolic effects, including increased visceral fat, muscle insulin resistance, and increased intramyocellular triglycerides, which are not seen with Intermittent Energy Restriction (IER) or Continuous Energy Restriction (CER).
If you are already lean, avoid total fasting (0 calories). It may cause your body to store fat in your muscles and liver, worsening insulin sensitivity. Stick to partial restriction (eating some food) if you want to try intermittent fasting.
Periods of IER each week will induce lipolysis and fluxes in FFAs... Single bouts of total fasts (24–48 h) in non-obese subjects have been associated with modest increases in hepatic and intramyocellular triglyceride content... IF regimens reduced energy intake and weight but increased visceral fat, fat cell size and had adverse effects on insulin sensitivity compared to heavier ad libitum fed animals
Why this rating
Based on small, short-term studies in non-obese subjects and animal models; clinical significance is uncertain.
Source
Potential Benefits and Harms of Intermittent Energy Restriction and Intermittent Fasting Amongst Obese, Overweight and Normal Weight Subjects—A Narrative Review of Human and Animal Evidence
Michelle Harvie et al. · Behavioral Sciences · 2017
DOI 10.3390/bs7010004
More from this paper
- Intermittent Energy Restriction (IER) produces weight loss and body fat reduction equivalent to Continuous Energy Restriction (CER) when total energy intake is matched, with some regimens showing superior fat loss due to better adherence.Moderate
- Intermittent Fasting (IF) and Intermittent Energy Restriction (IER) improve insulin sensitivity (HOMA-IR) to a greater extent than Continuous Energy Restriction (CER) in some studies, potentially due to rapid mobilization of visceral and hepatic fat.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →